Thymosin Alpha-1 Safety Profile
Safety profile of thymosin alpha-1 based on clinical trial data and international regulatory approvals.
Last updated: February 12, 2026
For Educational Purposes Only
This safety information is compiled from clinical trial data and regulatory documents for educational purposes. It is not a substitute for professional medical advice. Always consult your healthcare provider about medication safety, especially regarding your individual circumstances, medical history, and other medications.
Safety Overview
FDA Approval Status: Not approved in the United States. Approved in 30+ countries including China, Russia, and several Southeast Asian nations under the brand name Zadaxin for hepatitis B and hepatitis C treatment.
Level of Evidence: Moderate. Multiple Phase 2 and Phase 3 clinical trials conducted since the 1980s. The compound has been administered to thousands of patients in approved markets. Now off-patent, available as compounded formulations in the US.
Primary Indication: Thymic immunomodulation. Used clinically for chronic hepatitis B, hepatitis C (as adjunct to interferon), and cancer immunotherapy in approved markets.
Known Side Effects
| Frequency | Side Effect | Severity |
|---|---|---|
| Common (>5%) | Injection site reactions (redness, swelling) | Mild |
| Common (>5%) | Mild flu-like symptoms (fatigue, malaise) | Mild |
| Uncommon (1-5%) | Headache | Mild |
| Uncommon (1-5%) | Nausea | Mild |
| Rare (under 1%) | Allergic reactions | Mild to moderate |
Clinical Trial Safety Data
In a meta-analysis of hepatitis B trials, thymosin alpha-1 demonstrated a favorable safety profile with adverse event rates similar to placebo groups. Most adverse events were mild and transient.
Injection Site Reactions
The most commonly reported side effect. Subcutaneous administration can cause localized redness, swelling, or tenderness that typically resolves within 24-48 hours. Rotating injection sites reduces incidence.
Systemic Effects
Flu-like symptoms (fatigue, low-grade fever, muscle aches) reported in approximately 5-10% of patients in clinical trials. These effects are generally self-limiting and occur within hours of injection.
Key Safety Considerations
Immune System Modulation
Thymosin alpha-1 enhances T-cell function and promotes Th1 immune responses. Theoretical concern exists for exacerbating autoimmune conditions, though clinical trials have not demonstrated increased autoimmune adverse events.
Long-Term Safety
Long-term safety data (>12 months continuous use) is limited. Most clinical trials ranged from 12 weeks to 6 months. Zadaxin prescribing information in approved markets recommends periodic treatment courses rather than continuous administration.
Drug Interactions
No significant drug-drug interactions reported in clinical trials. Has been safely combined with interferon-alpha, lamivudine, and various chemotherapy regimens in clinical studies.
Contraindications
- Known hypersensitivity to thymosin alpha-1 or any formulation component
- Active autoimmune disease (relative contraindication—use with caution)
- Pregnancy and lactation (insufficient data)
Product Quality Risks
Critical Consideration: As an off-patent compound, thymosin alpha-1 is available from compounding pharmacies in the US without FDA oversight. Quality, purity, and potency vary significantly between suppliers.
Peptide Stability: Requires refrigeration (2-8°C). Degrades rapidly at room temperature. Improperly stored product may have reduced efficacy or altered safety profile.
Contamination Risk: Non-pharmaceutical-grade versions may contain bacterial endotoxins, aggregates, or impurities not present in approved Zadaxin formulations.
This safety information is based on published clinical trials and regulatory filings. Thymosin alpha-1 is not FDA-approved in the United States. Use of compounded formulations carries additional risks related to product quality and purity. Always consult qualified healthcare providers before use.
Safety Alerts
Get notified about new safety data, FDA decisions, and adverse event reports.
No spam. Unsubscribe anytime.
Important: Safety information evolves as post-marketing data accumulates. This page reflects data available as of the last update date. Check official FDA and EMA resources for the most current safety information. This content is not intended to diagnose, treat, cure, or prevent any disease.